New Russian antiretroviral expected to launch in next 3-4 years
A new drug for antiretroviral therapy is undergoing clinical trials at the Central Research Institute of Epidemiology of the Russian Federal Service on Surveillance for Consumer rights protection and human well-being (Rospotrebnadzor).
The new drug is scheduled for market launch already in 2020-2021, and will be an alternative for the strict regimen constant side effects associated with HIV treatment, reports The Pharma Letter’s local correspondent.
According to Dmitry Kireev, head of the group for developing new methods for diagnosing HIV infection and viral hepatitis of the Institute, the drug is made on the basis of nanosuspensions, which are slowly consumed in the body, being present in all tissues of the patient’s body at the right levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze